The narrative around David Sinclair’s XPrize entry taps into deep-seated desires for longevity and rejuvenation, a theme with both scientific promise and a history of hype. The strongest version of this story is that Sinclair is pushing the boundaries of epigenetic reprogramming, leveraging a competitive prize to accelerate human trials of a potentially groundbreaking oral drug. The XPrize’s emphasis on standardized metrics for aging is a welcome step toward scientific rigor in a field often pla...